Daily insulin injection, begun early with type 2 diabetes, neither increased nor reduced heart attack, stroke or cancer risk, Canadian researchers said. The Outcome Reduction with Initial Glargine Intervention trial randomized more than 12,500 people at high risk for, or in the early stages of, type 2 diabetes to either one daily injection of glargine, or insulin, or standard care -- no insulin -- over a median of 6.2 years. Principal investigator Dr. Hertzel Gerstein and Dr. Salim Yusuf of McMaster University in Hamilton, Ontario, found no difference among the two groups in cardiovascular outcomes or in the development of any type of cancer, suggesting daily insulin injection to normalize glucose levels is not harmful over long periods of time. Patients given insulin maintained glucose levels in the normal range -- 90-94 mg/dL -- throughout the duration of the study, the researchers said. Some previous research suggested a link between insulin use and an increased risk of heart attacks, strokes and several kinds of cancer, but none examined the long-term impacts of insulin use on serious cardiovascular outcomes and cancers in high-risk individuals, the researchers said. The findings were presented at the American Diabetes Association's 72nd scientific sessions in Philadelphia.
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkiller
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor